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Error in author list
Dr Melendez was incorrectly affiliated in “Chimeric design, 
synthesis, and biological assays of a new nonpeptide insulin-
mimetic vanadium compound to inhibit protein tyrosine 
phosphatase 1B”, published in Drug Design, Development 
and Therapy. The corrected list of authors and affiliations 
follows:
Thomas Scior1, José Antonio Guevara-García2, FJ Melendez1, 
Hassan H Abdallah3, Quoc-Tuan Do4, Philippe Bernard4
1Facultad de Ciencias Químicas, Universidad Autónoma de 
Puebla, Pue, Puebla, Mexico; 2Faculty of Basic Sciences, 
Technology and Engineering, Laboratory of Research in 
Bioinorganic and Bioremediation, Universidad Autónoma de 
Tlaxcala, Apizaco, Tlaxcala, México;  3School of Chemical 
Sciences, Universiti Sains Malaysia, Penang, Malaysia; 
4GreenPharma S.A., 3 Allée du Titane, Orléans, France